A Review of the Unique Drug Development Strategy of Indacaterol Acetate/Glycopyrronium Bromide/Mometasone Furoate: A First-in-Class, Once-Daily, Single-Inhaler, Fixed-Dose Combination Treatment for Asthma-Reference-Cited by-同舟云学术

A Review of the Unique Drug Development Strategy of Indacaterol Acetate/Glycopyrronium Bromide/Mometasone Furoate: A First-in-Class, Once-Daily, Single-Inhaler, Fixed-Dose Combination Treatment for Asthma

Published:2022-01-24 Issue:6 Volume:39 Page:2365-2378
ISSN:0741-238X
Container-title:Advances in Therapy
language:en
Short-container-title:Adv Ther

Author:

Brittain Dominic,D’Andrea Peter,Gruen Emilie,Hosoe Motoi,Jain Devendra,Jauernig Juergen,Pethe Abhijit,Scosyrev Emil,Tanase Ana-Maria,Tillmann Hanns-Christian

Funder

Novartis Pharma AG

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s12325-021-02025-w.pdf

Reference42 articles.

1. Enerzair® Breezhaler®. Summary of product characteristics (SmPC). Last updated 12 May 2021. https://www.medicines.org.uk/emc/product/11886/smpc#gref. Accessed 26 Sept 2021.

2. Atectura® Breezhaler®. Summary of product characteristics (SmPC). Last updated 11 Aug 2021. https://www.medicines.org.uk/emc/product/11885/smpc. Accessed 26 Sept 2021.

3. Novartis receives EC approval for Enerzair® Breezhaler®, including the first digital companion (sensor and app) that can be prescribed alongside a treatment for uncontrolled asthma in the EU. Media Release. https://www.novartis.com/news/media-releases/novartis-receives-ec-approval-enerzair-breezhaler-including-first-digital-companion-sensor-and-app-can-be-prescribed-alongside-treatment-uncontrolled-asthma-eu. Accessed 26 Sept 2021.

4. EMA’s transformative treatments of 2020. https://www.europeanpharmaceuticalreview.com/article/143977/emas-transformative-treatments-of-2020/. Accessed 26 Sept 2021.

5. Katsaounou P, Odemyr M, Spranger O, et al. Still fighting for breath: a patient survey of the challenges and impact of severe asthma. ERJ Open Res. 2018;4:00076–2018.

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Stepwise Approach in Asthma Revisited 2023: Expert Panel Opinion of Turkish Guideline of Asthma Diagnosis and Management Group;Thoracic Research and Practice;2023-10-31

2. Efficacy of mometasone/indacaterol/glycopyrronium in patients with inadequately controlled asthma with respect to baseline eosinophil count: Post hoc analysis of IRIDIUM study;Respiratory Medicine;2023-10

3. Plackett–Burman and face-centered composite designs for development and optimization of chromatographic method for the simultaneous determination of glycopyrronium, indacaterol and mometasone in their fixed dose combination inhaler – Green profile assessment;Journal of Pharmaceutical and Biomedical Analysis;2023-09

4. Efficacy of once-daily, single-inhaler, fixed-dose combination of mometasone/indacaterol/glycopyrronium in patients with asthma with or without persistent airflow limitation: Post hoc analysis from the IRIDIUM study;Respiratory Medicine;2023-05

5. Digital Therapeutics: Scientific, Technological, and Regulatory Challenges;Personalized Medicine Meets Artificial Intelligence;2023